Who Paid My Doc
Samir Jani
Pain Medicine Whiting, NJ Medical Doctor
NPI 1184912826 CMS profile 326505
1100 Route 70, Whiting, NJ 08759
General payments
$9,736
Research payments
$960
Ownership & investment interest
$50,000
Through program year 2025, Samir Jani of Whiting, NJ is reported in the CMS Open Payments database as having received $9,736 across 144 general payments and $960 in research payments paid to them. They also declared ownership or investment interests valued at $50,000 across 1 holding.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 82nd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $18 | 1 | |
| 2024 | General | $324 | 7 | |
| 2023 | General | $469 | 14 | |
| 2022 | General | $557 | 28 | |
| 2021 | General | $1,593 | 31 | |
| 2021 | Research | $140 | 1 | |
| 2020 | General | $3,238 | 20 | |
| 2020 | Research | $820 | 1 | |
| 2019 | General | $3,537 | 43 | |
| 2019 | Ownership | $50,000 | 1 |
Beside peers
- Samir Jani
- Pain Medicine median
- Middle half of Pain Medicine
- National median
In program year 2025, general payments to Samir Jani were reported at $18. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.
Show as a table
| Year | Samir Jani | Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $3,537 | $498 | $126–$1,682 | $163 |
| 2020 | $3,238 | $284 | $80–$910 | $114 |
| 2021 | $1,593 | $399 | $112–$1,219 | $132 |
| 2022 | $557 | $455 | $137–$1,484 | $149 |
| 2023 | $469 | $484 | $128–$1,495 | $160 |
| 2024 | $324 | $498 | $131–$1,540 | $164 |
| 2025 | $18 | $458 | $124–$1,401 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 50 drugsPart D claims
5,470
Drug cost
$354,188
Branded share of claims
35.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Oxycontin Oxycodone Hcl | Brand | 133 | $75,010 | |
| Percocet Oxycodone Hcl/Acetaminophen | Brand | 16 | $68,080 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 1,064 | $34,933 | |
| Xtampza Er Oxycodone Myristate | Brand | 55 | $30,968 | |
| Lidocaine | Generic | 121 | $16,052 | |
| Buprenorphine | Generic | 37 | $13,953 | |
| Oxycodone Hcl | Generic | 577 | $12,761 | |
| Fentanyl | Generic | 133 | $11,056 | |
| Lyrica Pregabalin | Brand | 11 | $9,642 | |
| Pregabalin | Generic | 271 | $7,460 |
The 10 drugs with the highest cost, of 50 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 82 billing codesPaid by Medicare
$970,332
Medicare patients
885
Services billed
45,347
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 42% | |
| Ischemic heart disease | 42% | |
| Depression | 40% | |
| COPD | 32% | |
| Chronic kidney disease | 27% | |
| Osteoporosis | 27% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 | Office | 38 | 3,900 | $22,147 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 47 | 248 | $182 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
146 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pain Medicine in New Jersey
Related records
Pain Medicine in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.